By Conjoint Professor David goldstein

Journal articles

Zhang BYH; Georgiou C; Turner C; Kee D; Goldstein D; Haurat J; Bourne A; Turner M; Scott CL, 2024, '39O Four years and 1400+ patient referrals: Achievements of the Australian Rare Cancer Portal', ESMO Open, 9, pp. 102428 - 102428, http://dx.doi.org/10.1016/j.esmoop.2024.102428

Sanz-Garcia E; Zou J; Avery L; Spreafico A; Waldron J; Goldstein D; Hansen A; Cho BCJ; de Almeida J; Hope A; Hosni A; Hahn E; Perez-Ordonez B; Zhao Z; Smith C; Zheng Y; Singaravelan N; Bratman SV; Siu LL, 2024, 'Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck', CELL DEATH AND DIFFERENTIATION, 31, pp. 460 - 468, http://dx.doi.org/10.1038/s41418-024-01272-y

Lam LL; Pavlakis N; Shitara K; Sjoquist KM; Martin AJ; Yip S; Kang YK; Bang YJ; Chen LT; Moehler M; Bekaii-Saab T; Alcindor T; O’Callaghan CJ; Tebbutt NC; Hague W; Chan H; Rha SY; Lee KW; Gebski V; Jaworski A; Zalcberg J; Price T; Simes J; Goldstein D, 2023, 'INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)', BMC Cancer, 23, http://dx.doi.org/10.1186/s12885-023-10642-7

Moore MJ; Goldstein D; Hamm J; Figer A; Hecht JR; Gallinger S; Au HJ; Murawa P; Walde D; Wolff RA; Campos D; Lim R; Ding K; Clark G; Voskoglou-Nomikos T; Ptasynski M; Parulekar W, 2023, 'Erlotinib Plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group', Journal of Clinical Oncology, 41, pp. 4714 - 4720, http://dx.doi.org/10.1200/JCO.22.02770

Gelderblom H; Jones RL; Blay JY; George S; von Mehren M; Zalcberg JR; Kang YK; Razak AA; Trent J; Attia S; Le Cesne A; Siontis BL; Goldstein D; Boye K; Sanchez C; Steeghs N; Rutkowski P; Druta M; Serrano C; Somaiah N; Chi P; Harrow B; Becker C; Reichmann W; Sherman ML; Ruiz-Soto R; Heinrich MC; Bauer S, 2023, 'Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study', European Journal of Cancer, 192, http://dx.doi.org/10.1016/j.ejca.2023.113245

Abdelmogod A; Papadopoulos L; Riordan S; Wong M; Weltman M; Lim R; McEvoy C; Fellowes A; Fox S; Bedő J; Penington J; Pham K; Hofmann O; Vissers JHA; Grimmond S; Ratnayake G; Christie M; Mitchell C; Murray WK; McClymont K; Luk P; Papenfuss AT; Kee D; Scott CL; Goldstein D; Barker HE, 2023, 'A Matched Molecular and Clinical Analysis of the Epithelioid Haemangioendothelioma Cohort in the Stafford Fox Rare Cancer Program and Contextual Literature Review', Cancers, 15, http://dx.doi.org/10.3390/cancers15174378

Mekapogu AR; Xu Z; Pothula S; Perera C; Pang T; Hosen SMZ; Damalanka V; Janetka J; Goldstein D; Pirola R; Wilson J; Apte M, 2023, 'HGF/c-Met pathway inhibition combined with chemotherapy increases cytotoxic T-cell infiltration and inhibits pancreatic tumour growth and metastasis', Cancer Letters, 568, http://dx.doi.org/10.1016/j.canlet.2023.216286

Clifford BK; Kaakoush NO; Tedla N; Goldstein D; Simar D, 2023, 'The effect of exercise intensity on the inflammatory profile of cancer survivors: A randomised crossover study', European Journal of Clinical Investigation, 53, pp. e13984, http://dx.doi.org/10.1111/eci.13984

Sjoquist KM; Martin A; Pavlakis N; Goldstein D; Tsobanis E; Moses D; Maher R; Hague W; Gebski V; Stockler MR; Simes RJ, 2023, 'Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer', Journal of Cancer Research and Clinical Oncology, 149, pp. 4959 - 4965, http://dx.doi.org/10.1007/s00432-022-04404-4

Thavaneswaran S; Lin FP-Y; Napier CE; Grady JP; Ballinger ML; Kansara M; Grimison PS; Pavlakis N; Wong MK; Sjoquist KM; Goldstein D; Chantrill LA; Simes J; Thomas DM, 2023, 'Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program', JOURNAL OF CLINICAL ONCOLOGY, 41, http://dx.doi.org/10.1200/JCO.2023.41.16_suppl.4093

Yeung N; Lin H-M; Timmins H; Li T; Goldstein D; Friedlander M; Harrison ML; Mahon KL; Meikle P; Park S; Horvath L, 2023, 'Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy.', JOURNAL OF CLINICAL ONCOLOGY, 41, http://dx.doi.org/10.1200/JCO.2023.41.16_suppl.3031

White D; Abdulla M; Park SB; Goldstein D; Moalem-Taylor G; Lees JG, 2023, 'Targeting translation: A review of preclinical animal models in the development of treatments for chemotherapy-induced peripheral neuropathy', Journal of the Peripheral Nervous System, 28, pp. 179 - 190, http://dx.doi.org/10.1111/jns.12544

Michael M; Wong R; Gill SS; Strickland AH; Pavlakis N; Shapiro JD; Link E; Farrell M; Ngan SY; Heriot AG; Goldstein D; Mitchell C; Wilson K; Mui M; Segelov E; MacCallum P, 2023, 'The Ave-Rec trial: Phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer-Toxicity and interim efficacy data.', JOURNAL OF CLINICAL ONCOLOGY, 41, http://dx.doi.org/10.1200/JCO.2023.41.16_suppl.3616

Tempero MA; Pelzer U; O'Reilly EM; Winter J; Oh DY; Li CP; Tortora G; Chang HM; Lopez CD; Bekaii-Saab T; Ko AH; Santoro A; Park JO; Noel MS; Frassineti GL; Shan YS; Dean A; Riess H; Van Cutsem E; Berlin J; Philip P; Moore M; Goldstein D; Tabernero J; Li M; Ferrara S; Le Bruchec Y; Zhang G; Lu B; Biankin AV; Reni M; Epstein R; Vasey P; Shapiro J; Burge M; Chua YJ; Harris M; Pavlakis N; Tebbutt N; Prager G; Dittrich C; Längle F; Philipp-Abbrederis K; Greil R; Stöger H; Girschikofsky M; Kuehr T; Van Laethem JL; Laurent S; Dhani N; Ko YJ; Dowden S; Kavan P; Tehfe MÉ; Kubala E; Kohoutek M; Pfeiffer P; Yilmaz M; Parner V; Salminen T; Soveri LM; Korkeila E; Osterlund P; Taieb J; Tougeron D; Artru P; Caroli-Bosc FX; Guimbaud R; Turpin A; Walter T; Bachet JB; Kunzmann V; Kreth F; Block A; Venerito M; Oettle H; Karthaus M; Trojan J; Folprecht G; Lerch M; Kullmann F; Reiser M; Heinemann V; Wörns MA; Schulz H; Garlipp B; Yau T; Chan LS; Juhasz B; Landherr L; Pinter T; Bodoky G; Kahán Z; McDermott R; Power D; Gianni L; Siena S; Milella M; Falcone A; Berardi R, 2023, 'Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results from a Randomized, Open-Label, Phase III Trial', Journal of Clinical Oncology, 41, pp. 2007 - 2019, http://dx.doi.org/10.1200/JCO.22.01134

Bekaii-Saab T; Okusaka T; Goldstein D; Oh DY; Ueno M; Ioka T; Fang W; Anderson EC; Noel MS; Reni M; Choi HJ; Goldberg JS; Oh SC; Li CP; Tabernero J; Li J; Foos E; Oh C; Van Cutsem E, 2023, 'Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial', Eclinicalmedicine, 58, http://dx.doi.org/10.1016/j.eclinm.2023.101897

Symons R; Daly D; Gandy R; Goldstein D; Aghmesheh M, 2023, 'Progress in the Treatment of Small Intestine Cancer', Current Treatment Options in Oncology, 24, pp. 241 - 261, http://dx.doi.org/10.1007/s11864-023-01058-3

Clifford BK; Amorim N; Kaakoush N; Boysen L; Tedla N; Goldstein D; Hardeman E; Simar D, 2023, 'Irradiation-Induced Dysbiosis: The Compounding Effect ofHigh-Fat Diet on Metabolic and Immune Functions in Mice', International Journal of Molecular Sciences, 24, pp. 5631 - 5631, http://dx.doi.org/10.3390/ijms24065631

Pavlakis N; Shitara K; Sjoquist KM; Martin AJ; Jaworski A; Yip S; Bang Y-J; Alcindor T; O'Callaghan CJ; Tebbutt NC; Strickland A; Rha SY; Lee K-W; Zalcberg JR; Price TJ; Simes J; Goldstein D, 2023, 'INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)-A study led by the Australasian Gastro-intestinal Trials Group (AGITG).', JOURNAL OF CLINICAL ONCOLOGY, 41, pp. LBA294 - LBA294

Timmins HC; Mizrahi D; Li T; Kiernan MC; Goldstein D; Park SB, 2023, 'Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review', Journal of Cancer Survivorship, 17, pp. 222 - 236, http://dx.doi.org/10.1007/s11764-021-00988-x

Li T; Timmins HC; Trinh T; Mizrahi D; Harrison M; Horvath LG; Grimison P; Friedlander M; Kiernan MC; King MT; Rutherford C; Goldstein D; Park SB, 2023, 'Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes', Jnccn Journal of the National Comprehensive Cancer Network, 21, pp. 125 - 132, http://dx.doi.org/10.6004/jnccn.2022.7074

Mizrahi D; Goldstein D; Trinh T; Li T; Timmins HC; Harrison M; Marx GM; Hovey EJ; Lewis CR; Friedlander M; Park SB, 2023, 'Physical activity behaviors in cancer survivors treated with neurotoxic chemotherapy', Asia-Pacific Journal of Clinical Oncology, 19, pp. 243 - 249, http://dx.doi.org/10.1111/ajco.13834

Lemech C; Dredge K; Bampton D; Hammond E; Clouston A; Waterhouse NJ; Stanley AC; Leveque-El Mouttie L; Chojnowski GM; Haydon A; Pavlakis N; Burge M; Brown MP; Goldstein D, 2023, 'Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors', Journal for Immunotherapy of Cancer, 11, http://dx.doi.org/10.1136/jitc-2022-006136

De Guzman RB; Chua MLK; Goldstein D; Aung S; Eaton V; Park K, 2023, 'ASCO's Leadership Development Program: Focusing on the Next Generation of Leaders in Asia Pacific', JCO Global Oncology, 9, http://dx.doi.org/10.1200/GO.22.00313

Michael M; Wong R; Gill S; Strickland A; Pavlakis N; Shapiro J; Link E; Farrell M; Ngan S; Heriot A; Goldstein D; Mitchell C; Wilson K; Mui M; Ramsay R; Segelov E, 2023, 'The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers', ANNALS OF ONCOLOGY, 34, pp. S450 - S450, http://dx.doi.org/10.1016/j.annonc.2023.09.1824

Hosen SMZ; Uddin MN; Xu Z; Buckley BJ; Perera C; Pang TCY; Mekapogu AR; Moni MA; Notta F; Gallinger S; Pirola R; Wilson J; Ranson M; Goldstein D; Apte M, 2022, 'Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU)', Frontiers in Immunology, 13, http://dx.doi.org/10.3389/fimmu.2022.1060957

Mahfouz FM; Park SB; Li T; Timmins HC; Horvath LG; Harrison M; Grimison P; King T; Goldstein D; Mizrahi D, 2022, 'Association of electrochemical skin conductance with neuropathy in chemotherapy-treated patients', Clinical Autonomic Research, 32, pp. 497 - 506, http://dx.doi.org/10.1007/s10286-022-00895-w

Siu DHW; Ali A; Tjokrowidjaja A; De Silva M; Lee J; Clingan PR; Aghmesheh M; Brungs D; Mapagu C; Goldstein D; O'Neill S; Liauw WS; Sjoquist KM; Thomas D; Pavlakis N; Clarke SJ; Diakos C; Chantrill LA, 2022, 'Clinical and molecular profile of young adults with early-onset colorectal cancer: Experience from four Australian tertiary centers', Asia Pacific Journal of Clinical Oncology, 18, pp. 660 - 668, http://dx.doi.org/10.1111/ajco.13745

Hooshmand K; Goldstein D; Timmins HC; Li T; Harrison M; Friedlander ML; Lewis CR; Lees JG; Moalem-Taylor G; Guennewig B; Park SB; Kwok JB, 2022, 'Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study', Journal of Translational Medicine, 20, http://dx.doi.org/10.1186/s12967-022-03754-4

Chiang JCB; Khou V; Tavakoli A; Park SB; Goldstein D; Krishnan AV; Markoulli M, 2022, 'Reproducibility and Reliability of Subbasal Corneal Nerve Parameters of the Inferior Whorl in the Neurotoxic and Healthy Cornea', Cornea, 41, pp. 1487 - 1494, http://dx.doi.org/10.1097/ICO.0000000000002947

Kokkinos J; Sharbeen G; Youkhana J; Boyer C; Goldstein D; Haghighi KS; McCarroll JA; Phillips PA, 2022, 'Abstract B076: βIII-Tubulin is a brake on extrinsic cell-death in pancreatic cancer', Cancer Research, 82, pp. B076 - B076, http://dx.doi.org/10.1158/1538-7445.panca22-b076

Kokkinos J; Sharbeen G; Haghighi KS; Youkhana J; Raina A; Pitiyarachchi O; Truong Q; Wenholz D; Laczka O; Kumar N; Goldstein D; Phillips PA, 2022, 'Abstract C073: CRO-67 is a novel therapeutic for pancreatic cancer: Implications for tumor and stromal reprogramming', Cancer Research, 82, pp. C073 - C073, http://dx.doi.org/10.1158/1538-7445.panca22-c073

Li T; Park SB; Battaglini E; King MT; Kiernan MC; Goldstein D; Rutherford C, 2022, 'Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use', Quality of Life Research, 31, pp. 3091 - 3107, http://dx.doi.org/10.1007/s11136-022-03154-7

Chiang JCB; Goldstein D; Trinh T; Au K; Park SB; Krishnan AV; Markoulli M, 2022, 'Tear film substance P in patients treated with neurotoxic chemotherapy', Experimental Eye Research, 224, http://dx.doi.org/10.1016/j.exer.2022.109253

Miller CN; Althoff KN; Schlueter DJ; Anton-Culver H; Chen Q; Garbett S; Ratsimbazafy F; Thomsen I; Karlson EW; Cicek M; Pinto LA; Malin BA; Ohno-Machado L; Williams C; Goldstein D; Kouame A; Ramirez A; Gebo KA; Schully SD, 2022, 'Concordance of SARS-CoV-2 Antibody Results during a Period of Low Prevalence', MSPHERE, 7, http://dx.doi.org/10.1128/msphere.00257-22

Mcnamara MG; Bridgewater J; Goyal L; Jacobs T; Wagner AD; Goldstein D; Shroff R; Moehler M; Lowery M; Bekaii-Saab T; Kelley RK; Furuse J; Rimassa L; Morizane C; Lamarca A; Hubner R; Knox J; Valle J, 2022, 'What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literature', BMJ Open, 12, http://dx.doi.org/10.1136/bmjopen-2022-064954

Best MC; Bartley N; Napier CE; Fisher A; Ballinger ML; Thomas DM; Goldstein D; Tucker K; Biesecker BB; Butow P, 2022, 'Return of comprehensive tumour genomic profiling results to advanced cancer patients: a qualitative study', Supportive Care in Cancer, 30, pp. 8201 - 8210, http://dx.doi.org/10.1007/s00520-022-07272-3

Mizrahi D; Goldstein D; Kiernan MC; Robinson L; Pitiyarachchi O; McCullough S; Mendoza-Jones P; Grimison P; Boyle F; Park SB, 2022, 'Development and consensus process for a clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathy', Supportive Care in Cancer, 30, pp. 5965 - 5974, http://dx.doi.org/10.1007/s00520-022-07024-3

Butow PN; Best MC; Davies G; Schlub T; Napier CE; Bartley N; Ballinger ML; Juraskova I; Meiser B; Goldstein D; Biesecker B; Thomas DM, 2022, 'Psychological impact of comprehensive tumor genomic profiling results for advanced cancer patients', Patient Education and Counseling, 105, pp. 2206 - 2216, http://dx.doi.org/10.1016/j.pec.2022.01.011

Krasovitsky MS; Goldstein D, 2022, 'Destructive soft tissue metastases in advanced colorectal cancer: a case report', Annals of Palliative Medicine, 11, pp. 2170 - 2174, http://dx.doi.org/10.21037/apm-21-362

Maharaj AD; Evans SM; Ioannou LJ; Croagh D; Earnest A; Holland JF; Pilgrim CHC; Neale RE; Goldstein D; Kench JG; Merrett ND; White K; Burmeister EA; Evans PM; Hayes TM; Houli N; Knowles B; Leong T; Nikfarjam M; Philip J; Quinn M; Shapiro J; Smith MD; Spillane JB; Wong R; Zalcberg JR, 2022, 'The association between quality care and outcomes for a real-world population of Australian patients diagnosed with pancreatic cancer', HPB, 24, pp. 950 - 962, http://dx.doi.org/10.1016/j.hpb.2021.11.005

Papadopoulos L; Georgiou CL; Kee D; Caldwell R; Bourne A; Haurat J; Turner M; Goldstein D; Scott CL, 2022, 'The psychosocial impact of the Australian Rare Cancer Portal on patients with rare cancer.', Journal of Clinical Oncology, 40, pp. e24127 - e24127, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e24127

Georgiou CL; Kee D; Papadopoulos L; Caldwell R; Bourne A; Haurat J; Turner M; Goldstein D; Scott CL, 2022, 'Two years of the Australian Rare Cancer Portal: a national referral service for rare cancer information and research.', Journal of Clinical Oncology, 40, pp. e18581 - e18581, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e18581

Timmins HC; Li T; Goldstein D; Trinh T; Mizrahi D; Harrison M; Horvath LG; Friedlander M; Kiernan MC; Park SB, 2022, 'The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors', Journal of Cancer Survivorship, 16, pp. 223 - 232, http://dx.doi.org/10.1007/s11764-021-01012-y

Rahman B; McEwen A; Phillips JL; Tucker K; Goldstein D; Jacobs C, 2022, 'Genetic and genomic learning needs of oncologists and oncology nurses in the era of precision medicine: A scoping review', Personalized Medicine, 19, pp. 139 - 153, http://dx.doi.org/10.2217/pme-2021-0096

Meiser B; Butow P; Davies G; Napier CE; Schlub TE; Bartley N; Juraskova I; Ballinger ML; Thomas DM; Tucker K; Goldstein D; Biesecker BB; Best MC; Young M-A, 2022, 'Psychological predictors of advanced cancer patients’ preferences for return of results from comprehensive tumor genomic profiling', American Journal of Medical Genetics Part A, 188, pp. 725 - 734, http://dx.doi.org/10.1002/ajmg.a.62563

Foo T; Goldstein D; Segelov E; Shapiro J; Pavlakis N; Desai J; Yip D; Zalcberg J; Price TJ; Nagrial A; Chantrill L; Burge M; Karapetis CS; Tebbutt N; Roy AC, 2022, 'The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours', Targeted Oncology, 17, pp. 95 - 110, http://dx.doi.org/10.1007/s11523-022-00869-y

Menant JC; Goldstein D; Au K; Trinh T; van Schooten KS; McCrary JM; Harris CA; Forster BC; Park SB, 2022, 'Corrigendum to “Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy” [Gait Posture 89 (2021) 178–185](S0966636221002514)(10.1016/j.gaitpost.2021.07.010)', Gait and Posture, 92, pp. 1, http://dx.doi.org/10.1016/j.gaitpost.2021.11.006

Bartley N; Best MC; Biesecker BB; Fisher A; Goldstein D; Meiser B; Thomas DM; Ballinger ML; Butow P, 2022, 'Effectively communicating comprehensive tumor genomic profiling results: Mitigating uncertainty for advanced cancer patients', Patient Education and Counseling, 105, pp. 452 - 459, http://dx.doi.org/10.1016/j.pec.2021.05.018

Pavlakis N; Shitara K; Sjoquist KM; Martin AJ; Jaworski A; Yip S; Oh D-Y; Moehler MH; Bekaii-Saab TS; Simes J; Goldstein D, 2022, 'INTEGRATE IIb: A randomized phase III open label study of regorafenib plus nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC)', JOURNAL OF CLINICAL ONCOLOGY, 40, http://dx.doi.org/10.1200/JCO.2022.40.4_suppl.TPS366

Butow P; Davies G; Napier CE; Bartley N; Ballinger ML; Biesecker B; Juraskova I; Meiser B; Schlub T; Thomas DM; Goldstein D; Best MC, 2022, 'Value of whole-genome sequencing to Australian cancer patients and their first-degree relatives participating in a genomic sequencing study', Journal of Genetic Counseling, 31, pp. 96 - 108, http://dx.doi.org/10.1002/jgc4.1455

Back to profile page